Plavix Sales Measures Complicated By Inconsistencies With IMS Data – BMS
Executive Summary
"Significant" variability in the prescription volume data reported by market researcher IMS Health has prompted Bristol-Myers Squibb to revise the way it tracks the performance of its anti-clotting drug Plavix (clopidogrel) in recent months
You may also be interested in...
Bristol Readies For Prasugrel’s Impact On Plavix, Files DPP-4 Inhibitor
Despite downplaying any concern, Bristol-Myers Squibb is preparing for a potential challenge to its blockbuster anti-clotting drug Plavix from Lilly/Daiichi Sankyo's Effient (prasugrel)
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.